A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Issued on behalf of Avaí Bio, Inc. (OTCQB: AVAI) LAS VEGAS, July 21, 2026 /PRNewswire/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and...
Issued on behalf of Avaí Bio, Inc. (OTCQB: AVAI) LAS VEGAS, July 21, 2026 /PRNewswire/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.